- $2.05bn
- $2.13bn
- $120.25m
Brief: Mesoblast Says Q1 Net Revenues Up 44%
Australia's Mesoblast hits one-month high on upbeat quarterly update
Australia's Mesoblast drops as Bell Potter cuts target price after key drug misses sales view
Brief: Mesoblast Says FDA Approves New Potency Assay For Commercial Ryoncil
Australia's Mesoblast rises on FDA approval for new potency assay for commercial Ryoncil
Brief: Mesoblast Anticipate To Incur Significant Losses For Foreseeable Future
Brief: Mesoblast Posts Q4 Ryoncil Net Revenue $36 Million
Brief: Mesoblast Says CEO Makes Investment To Increase Share Ownership
Australia's Mesoblast extends gains on upbeat Ryoncil cell therapy earnings
Australia's Mesoblast hits over two week high on upbeat Ryoncil revenue
Brief: Mesoblast Posts Ryoncil Q4 Net Revenue Of $36M
Brief: Mesoblast Requests Modular Review Of BLA For Rexlemestrocel-L In End-Stage Heart Failure With LVAD
Brief: Mesoblast Reports QTRLY Ryoncil Net Revenues Of $30.3 Million
ASX-shares of Mesoblast rise after back-treatment drug hits patent target
Australia's Mesoblast soars on bagging licence for Mayo Clinic-developed tech
Brief: Mesoblast Acquires CAR Platform For Precision-Enhanced Cell Products
Brief: Mesoblast Says Ryoncil's Net Revenue For Quarter Increases To US$30.3M
Brief: Mesoblast Posts HY Total Revenues $51.3 Million
Brief: Mesoblast Sees Full-Year Fiscal 2026 Ryoncil Net Revenue To Range Between $110 Million And $120 Million